Literature DB >> 33512437

Hematologic disorder-associated Cxcr4 gain-of-function mutation leads to uncontrolled extrafollicular immune response.

Nagham Alouche1,2, Amélie Bonaud1,3,4, Vincent Rondeau1,3,4, Rim Hussein-Agha1, Julie Nguyen2, Valeria Bisio1,3,4, Mélanie Khamyath1,3,4, Etienne Crickx5, Niclas Setterblad6, Nicolas Dulphy1,3,4, Matthieu Mahevas5, David H McDermott7, Philip M Murphy7, Karl Balabanian1,3,4, Marion Espéli1,3,4.   

Abstract

The extrafollicular immune response is essential to generate a rapid but transient wave of protective antibodies during infection. Despite its importance, the molecular mechanisms controlling this first response are poorly understood. Here, we demonstrate that enhanced Cxcr4 signaling caused by defective receptor desensitization leads to exacerbated extrafollicular B-cell response. Using a mouse model bearing a gain-of-function mutation of Cxcr4 described in 2 human hematologic disorders, warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome and Waldenström macroglobulinemia, we demonstrated that mutant B cells exhibited enhanced mechanistic target of rapamycin signaling, cycled more, and differentiated more potently into plasma cells than wild-type B cells after Toll-like receptor (TLR) stimulation. Moreover, Cxcr4 gain of function promoted enhanced homing and persistence of immature plasma cells in the bone marrow, a phenomenon recapitulated in WHIM syndrome patient samples. This translated in increased and more sustained production of antibodies after T-independent immunization in Cxcr4 mutant mice. Thus, our results establish that fine-tuning of Cxcr4 signaling is essential to limit the strength and length of the extrafollicular immune response.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33512437      PMCID: PMC8176768          DOI: 10.1182/blood.2020007450

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  46 in total

1.  CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.

Authors:  Jorge J Castillo; Lian Xu; Joshua N Gustine; Andrew Keezer; Kirsten Meid; Toni E Dubeau; Xia Liu; Maria G Demos; Amanda Kofides; Nicholas Tsakmaklis; Jiaji G Chen; Manit Munshi; Maria L Guerrera; Gloria G Chan; Christopher J Patterson; Guang Yang; Zachary R Hunter; Steven P Treon
Journal:  Br J Haematol       Date:  2019-07-03       Impact factor: 6.998

Review 2.  Plasma cell development: from B-cell subsets to long-term survival niches.

Authors:  Kirsten A Fairfax; Axel Kallies; Stephen L Nutt; David M Tarlinton
Journal:  Semin Immunol       Date:  2008-01-28       Impact factor: 11.130

3.  The bone marrow microenvironment in waldenstrom macroglobulinemia.

Authors:  Irene M Ghobrial; Patricia Maiso; Abdelkareem Azab; Yang Liu; Yong Zhang; Ghayas Issa; Feda Azab; Antonio Sacco; Phong Quang; Hai Ngo; Aldo Roccaro
Journal:  Ther Adv Hematol       Date:  2011-08

4.  Proper desensitization of CXCR4 is required for lymphocyte development and peripheral compartmentalization in mice.

Authors:  Karl Balabanian; Emilie Brotin; Vincent Biajoux; Laurence Bouchet-Delbos; Elodie Lainey; Odile Fenneteau; Dominique Bonnet; Laurence Fiette; Dominique Emilie; Françoise Bachelerie
Journal:  Blood       Date:  2012-03-20       Impact factor: 22.113

5.  C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma.

Authors:  Aldo M Roccaro; Antonio Sacco; Cristina Jimenez; Patricia Maiso; Michele Moschetta; Yuji Mishima; Yosra Aljawai; Ilyas Sahin; Michelle Kuhne; Pina Cardarelli; Lewis Cohen; Jesus F San Miguel; Ramon Garcia-Sanz; Irene M Ghobrial
Journal:  Blood       Date:  2014-04-07       Impact factor: 22.113

6.  WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12.

Authors:  Karl Balabanian; Bernard Lagane; José Luis Pablos; Lysiane Laurent; Thierry Planchenault; Olivier Verola; Celeste Lebbe; Delphine Kerob; Alain Dupuy; Olivier Hermine; Jean-François Nicolas; Véronique Latger-Cannard; Danièle Bensoussan; Pierre Bordigoni; Françoise Baleux; Françoise Le Deist; Jean-Louis Virelizier; Fernando Arenzana-Seisdedos; Françoise Bachelerie
Journal:  Blood       Date:  2004-11-09       Impact factor: 22.113

7.  Suppression of B cell activation by cyclosporin A, FK506 and rapamycin.

Authors:  L S Wicker; R C Boltz; V Matt; E A Nichols; L B Peterson; N H Sigal
Journal:  Eur J Immunol       Date:  1990-10       Impact factor: 5.532

8.  Crosstalk between CXCR4/stromal derived factor-1 and VLA-4/VCAM-1 pathways regulates neutrophil retention in the bone marrow.

Authors:  Joseph M Petty; Christopher C Lenox; Daniel J Weiss; Matthew E Poynter; Benjamin T Suratt
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

9.  CXCL12 Mediates Aberrant Costimulation of B Lymphocytes in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Immunodeficiency.

Authors:  Giuliana Roselli; Elisa Martini; Vassilios Lougaris; Raffaele Badolato; Antonella Viola; Marinos Kallikourdis
Journal:  Front Immunol       Date:  2017-09-04       Impact factor: 7.561

10.  Germinal center centroblasts transition to a centrocyte phenotype according to a timed program and depend on the dark zone for effective selection.

Authors:  Oliver Bannard; Robert M Horton; Christopher D C Allen; Jinping An; Takashi Nagasawa; Jason G Cyster
Journal:  Immunity       Date:  2013-10-31       Impact factor: 31.745

View more
  3 in total

1.  An Extended Prognostic Index of the ISSWM Score Based on Thyroid Complications in Waldenström Macroglobulinemia/Lymphoplasmacytoid Lymphoma.

Authors:  Xinting Hu; Hua Wang; Dai Yuan; Huiting Qu; Ying Li; Na Wang; Xianghua Wang; Xin Liu; Hongzhi Xu; Ya Zhang; Xin Wang
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

Review 2.  Hematopoietic Multipotent Progenitors and Plasma Cells: Neighbors or Roommates in the Mouse Bone Marrow Ecosystem?

Authors:  Amélie Bonaud; Julia P Lemos; Marion Espéli; Karl Balabanian
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

3.  CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.

Authors:  Ulrich Keller; Stefan Habringer; Richard Lewis; H Carlo Maurer; Nikita Singh; Irene Gonzalez-Menendez; Matthias Wirth; Markus Schick; Le Zhang; Konstandina Isaakidis; Anna Katharina Scherger; Veronika Schulze; Junyan Lu; Thorsten Zenz; Katja Steiger; Roland Rad; Leticia Quintanilla-Martinez; Marion Espeli; Karl Balabanian
Journal:  Leukemia       Date:  2021-08-06       Impact factor: 11.528

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.